Phenotypes Associated with This Genotype

Genotype
MGI:4835041

• Allelic Composition: Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh; Kras^tm4Tyj/Kras⁺; Trp53^tm1Brn/Trp53^tm1Brn; Tg(Tyr-cre/ERT2)13Bos/0
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:164588 )

• all mice treated with tamoxifen neonatally die within 14 weeks of treatment due to aggressive melanomas with spindle-like morphology unlike control mice in which only one mouse develops melanoma over a period of 60 weeks

neoplasm

increased tumor growth/size ( J:164588 )

• tumor growth is more aggressive than in Cdkn2a^tm1Rdp/Cdkn2a^tm1Rdp Tg(Tyr-HRAS)60Lc mice

increased spindle cell carcinoma incidence ( J:164588 )

• tamoxifen-treated mice develop melanomas with spindle-like morphology

increased melanoma incidence ( J:164588 )

• all mice treated with tamoxifen neonatally die within 14 weeks of treatment due to aggressive melanomas with spindle-like morphology unlike control mice in which only one mouse develops melanoma over a period of 60 weeks

• tumors in tamoxifen-treated mice occur on the flank, ear, and tail

• the number of tumors in tamoxifen-treated mice is greater than in similarly treated Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Kras^tm4Tyj/Kras⁺ Tg(Tyr-cre/ERT2)13Bos mice or Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53^tm1Brn Tg(Tyr-cre/ERT2)13Bos mice

• by 15 weeks, 17 of 27 adult mice treated with tamoxifen develop melanomas at the site of application and depilation

• however, no uveal tumors are observed

pigmentation

abnormal melanocyte morphology ( J:164588 )

• tamoxifen-treated mice exhibit melanocytic proliferation unlike wild-type mice

hyperpigmentation ( J:164588 )

• tamoxifen-treated mice develop pigmented macules in the paws and tail unlike wild-type mice